Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 219-660-8 | CAS number: 2492-26-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Carcinogenicity
Administrative data
Description of key information
There are no valid chronic toxicity studies or carcinogenicity studies available for SMBT. A read across approach (systemic effects) was conducted with study data from MBT (benzothiazole-2-thiol) (see discussion endpoint summary toxicokinetics). No carcinogenic activity was reported in the chronic carcinogenicity study in mice treated with MBT and no clear MBT related carcinogenic activity can be concluded from the chronic rat study.
Key value for chemical safety assessment
Justification for classification or non-classification
No classification is required according to the classification criteria 67/548/EWG and regulation no. 1272/2008 (GHS).
Additional information
There are no valid chronic toxicity studies or carcinogenicity studies available for SMBT.
A read across approach (systemic effects) was conducted with study data from MBT (benzothiazole-2-thiol) (see discussion endpoint summary toxicokinetics).
Read-across approach with MBT (systemic effects)
In a carcinogenicity study (NTP 1988) male and female Fischer 344 rats were administered with MBT for 103 weeks. Groups of 50 male rats were administered 0, 375, or 750 mg/kg 2-mercaptobenzothiazole in corn oil by gavage, 5 days per week for 103 weeks. Groups of 50 female rats were administered 0, 188, or 375 mg/kg 2-mercaptobenzothiazole in corn oil by gavage on the same schedule. For further details on material and methods and non-neoplastic outcome see chapter repeated dose toxicity.
The authors of the study reported evidence of increased incidences of monocular cell leukemia, pancreatic acinar cell adenomas, adrenal gland pheochromocytomas, and preputial gland adenomas or carcinomas (combined) in males and increased incidences of adrenal gland pheochromocytomas and piutiary gland adenomas in females.
However, the increase in mononuclear cell leukemia, pituitary gland adenomas and pancretic acinar cell adenomas in male rats were increased only in the low dose groups and thus not dose-dependent. The incidences of adrenal gland pheochromocytomas, and prepuitial gland adenomas or carcinomas (combined) were significant increased in low and high dose males. The increase noted was more pronounced in the low dose group than in the high dose group; thus no clear dose-effect relationship was revealed. In high dose females incidences of adenomas of the pituitary gland and adrenal gland pheochromocytomas were significant increased and occurred with significant positive trend. The observed incidences were within the bounds of historical control range. However, the relevance of adrenal gland pheochromocytomas in rats is questionable. Recent data analysis revealed that occurrence of pheochromocytomas in MBT treated rats, is associated with nephrotoxicity associated with endocrine disturbance (Greim 2009). The relevance of this finding for human is questionable. In addition it should be noted that the study is severely comprised by the poor survival rate in male rats, indicating that MTD (maximum tolerated dose) was presumable exceeded, and by the fact of the higher tumor rates in the low dose than in the high dose group in general (absence of a dose-response relationship). The observed differences in the tumor incidences of dosed animals compared to the concurrent controls do not appear to be significant when historical controls are taken into account. The overall rates of individual tumors in treated animals do not exceed the historical range. Overall, no clear carcinogenic activity can be concluded from this study.
In an additional NTP carcinogenicity study male and female B6C3F1 mice were administered with MBT for 103 weeks (NTP 1988). Groups of 50 male and 50 female mice were administered 0, 375, or 750 mg/kg 2-mercaptobenzothiazole in corn oil by gavage, 5 days per week for 103 weeks. For further details on material and methods and non-neoplastic outcome see chapter repeated dose toxicity. The Pathological and histopathological incidences of non-neoplastic lesions were in the range of the vehicle control. Neoplastic lesions noted were within the historical control data range.
Overall, no carcinogenic activity was reported in the chronic carcinogenicity study in mice and no clear MBT related carcinogenic activity can be concluded from the chronic rat study.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.